Rapid weight gain in infliximab treated Crohn’s disease patients is sustained over time: real-life data over 12 months

References

• Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367–1374.
   PubMed Web of Science ®Google Scholar
• Saad AA, Symmons DP, Noyce PR, et al. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol. 2008;35:883–890.
   PubMed Web of Science ®Google Scholar
• Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med. 2006;355:704–712.
   PubMed Web of Science ®Google Scholar
• Gorman JD, Sack KE, Davis JC. Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002;346(18):1349–1356.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6(6):644–653.
   PubMed Web of Science ®Google Scholar
• Yang HZ, Wang K, Jin HZ, et al. Infliximab monotheraphy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo- controlled multicenter trial. Chin Med J. 2012;125:1845–1851.
   PubMed Web of Science ®Google Scholar
• Altwegg R, Vincent T. TNF blocking therapies and immunomonitoring in patients with inflammatory bowel disease. Mediators Inflammation. 2014;2014:172821.
   PubMed Web of Science ®Google Scholar
• Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to- severe Crohn’s disease in children. Gastroenterology. 2007;132(3):863–873.
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s disease cA2 study group. N Engl J Med. 1997;337(15):1029–1035.
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–1405.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I study group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–1549.
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350(9):876–885.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476.
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348(7):601–608.
   PubMed Web of Science ®Google Scholar
• Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology. 2009;137:1628–1640.
   PubMed Web of Science ®Google Scholar
• Loftus EV. Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–1517.
   PubMed Web of Science ®Google Scholar
• Renzo LD, Saraceno R, Schipani C, et al. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-a treatment. Dermatol Ther. 2011;24:446–451.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Cotena C, Tessari G, et al. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venerol. 2008;22(3):341–344.
   PubMed Web of Science ®Google Scholar
• Saraceno R, Schipani C, Mazzotta A, et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res. 2008;57:290–295.
   PubMed Web of Science ®Google Scholar
• Argiles JM, Lopez-Soriano J, Busquets S, et al. Journey from cachexia to obesity by TNF. Faseb J. 1997;11:743–751.
   PubMed Web of Science ®Google Scholar
• Briot K, Garnero P, Le Henanff A, et al. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor α treatment. Ann Rheum Dis. 2005;64:1137–1140.
   PubMed Web of Science ®Google Scholar
• Briot K, Gossec L, Kolta S, et al. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor-alpha treatment. J Rheumatol. 2008;35:855–861.
   PubMed Web of Science ®Google Scholar
• Florin V, Cottencin AC, Delaporte E, et al. Body weight increment in patients treated with infliximab for plaque psoriasis. J Eur Acad Dermatol Venereol. 2013;27:e186–e190.
   PubMed Web of Science ®Google Scholar
• Franchimont D, Roland S, Gustot T, et al. Impact of infliximab on serum leptin level in patients with Crohn’s disease. J Clin Endocrinol Metab. 2005;90(6):3510–3516.
   PubMed Web of Science ®Google Scholar
• Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753.
   PubMed Web of Science ®Google Scholar
• World Health Organisation Europe: Health topics; BMI. Copenhagen: WHO. 2020 [cited 2020 May 8]. Available from: http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi
   Google Scholar
• Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60:505–512.
   PubMed Web of Science ®Google Scholar
• Kim MJ, Lee WY, Choi KE, et al. Effect of Infliximab ‘Top-down’ Therapy on weight gain in Pediatric Crohn’s Disease. Indian Pediatr. 2012;49:979–982.
   PubMed Web of Science ®Google Scholar
• Vadan R, Gheorghe LS, Constantinescu A, et al. The prevalence of malnutrition and the evolution of nutritional status in patients with moderate to severe forms of Crohn’s disease treated with infliximab. Clin Nutr. 2011;30:86–91.
   PubMed Web of Science ®Google Scholar
• Diamanti A, Basso MS, Gambarara M, et al. Positive impact of blocking tumor necrosis factor alfa on the nutritional status in pediatric crohn’s disease patients. Int J Colorectal Dis. 2009;24(1):19–25.
   PubMed Web of Science ®Google Scholar
• Nakahigashi M, Yamamoto T. Increases in body mass index during infliximab therapy in patients with Crohn’s disease: an open label prospective study. Cytokine. 2011;56(2):531–535.
   PubMed Web of Science ®Google Scholar
• Weise D, Lashner B, Seidner D. Measurment of nutrition status in Crohn’s disease patients receiving infliximab therapy. Nutr Clin Pract. 2008;23:551–556.
   PubMed Web of Science ®Google Scholar
• Haas L, Chevalier R, Major BT, et al. Biologic agents are associated with excessive weight gain in children with inflammatory bowel disease. Dig Dis Sci. 2017;62(11):3110–3116.
   PubMed Web of Science ®Google Scholar
• Christian KE, Russman KM, Rajan DP, et al. Gender differences and other factors associated with weight gain following initiation of infliximab: a post hoc analysis of clinical trials. Inflamm Bowel Dis. 2020;26(1):125–131.
   PubMed Web of Science ®Google Scholar
• Koutroubakis IE, Oustamanolakis P, Malliaraki N, et al. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2009;21:283–288.
   PubMed Web of Science ®Google Scholar
• Mahe E, Reguiai Z, Barthelemy H, et al. Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross-sectional study. J Eur Acad Dermatol Venereol. 2014;28:151–159.
   PubMed Web of Science ®Google Scholar
• Tan E, Baker C, Foley P. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis. Aust J Dermatol. 2013;54:259–263.
   PubMed Web of Science ®Google Scholar
• Metsios GS, Stavropoulos-Kalinoglou A, Douglas KM, et al. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of Rheumatoid cachexia. Rheumatology. 2007;46(12):1824–1827.
   PubMed Web of Science ®Google Scholar
• Marcora SM, Chester KR, Mittal G, et al. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr. 2006;84(6):1463–1472.
   PubMed Web of Science ®Google Scholar
• Engvall IL, Tengstrand B, Brismar K, et al. Infliximab therapy increases body fat mass in early Rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomized study over 21 months. Arhritis Res Ther. 2010;12:R197.
   PubMed Web of Science ®Google Scholar
• Brown RA, Spina D, Butt S, et al. Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis. Clin Rheumatol. 2012;31:455–461.
   PubMed Web of Science ®Google Scholar
• Sfriso P, Caso F, Filardo GS, et al. Impact of 24 months of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study. Clin Rheumatol. 2016;35:1615–1618.
   PubMed Web of Science ®Google Scholar